Pfizer, the US multinational pharmaceutical company, is strategically focusing on India as a key market for its next growth wave, particularly in oncology, obesity treatments, and vaccines. Meenakshi Nevatia, the country president of Pfizer India, emphasized that India is essential for any multinational's global success. The company aims to launch new therapies rapidly while ensuring they are priced appropriately for the Indian market. Notably, 70% of Pfizer India's sales are generated from products manufactured locally. Recently, Pfizer launched three new products, including the Prevenar 20 adult pneumococcal vaccine and Emblaveo, which are designed to be affordable and accessible. Furthermore, Pfizer is expanding its focus on obesity through its $10 billion acquisition of Metsera, which aims to introduce innovative treatments with local clinical studies. The company is also advocating for regulatory data protection to maintain its competitive edge in the market.